Evidence map›Paper›PMID 40155826›Full record

ArticleInternational journal of emergency medicine2025

Posterior ischemic optic neuropathy following continuous renal replacement therapy: a case report.

Hiro Takefuji, Junpei Komagamine

Abstract read
In one paragraph

Article in International journal of emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hiro TakefujiDepartment of Emergency and Critical Care Medicine, NHO Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro, Tokyo, Tokyo, Japan. hrsdcc117@gmail.com.
Junpei KomagamineDepartment of Emergency and Critical Care Medicine, NHO Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro, Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPosterior ischemic optic neuropathy (PION) is a rare cause of acute vision loss in intensive care unit patients. PION following continuous renal replacement therapy (CRRT) hemodialysis has not ever been reported. Here, we report a case of bilateral nonarteritic PION following the initiation of CRRT. CASE PRESENTATION: A 52-year-old man with hypertension and stage 4 chronic kidney disease was admitted due to metabolic acidosis, hyperkalemia, and acute exacerbation of CKD. CRRT caused transient hypotension upon initiation but corrected the metabolic acidosis and hyperkalemia six hours after initiation. Therefore, CRRT was stopped. However, several hours after the cessation of CRRT, the patient experienced sudden, painless vision loss in both eyes. Assessment of his visual acuity revealed the inability to perceive light in both eyes. There were no symptoms or signs of giant cell arteritis. An ophthalmological examination revealed no abnormalities. Magnetic resonance imaging of the brain revealed no compressive lesions or acute stroke, but magnetic resonance angiography revealed stenosis of both the bilateral carotid artery and the right middle cerebral artery. Administration of a high dose of corticosteroids did not reverse his vision loss. Thus, nonarteritic PION following CRRT was diagnosed.

conclusionsPION should be considered if a patient with multiple vascular risk factors complains of sudden painless vision loss without signs of optic disk edema after the initiation of CRRT. Preventing blood pressure drops during the initiation of CRRT in patients with multiple vascular risk factors may prevent PION.

Indexed as

Continuous renal replacement therapyPosterior ischemic optic neuropathyVisual loss

Identifiers

PMID40155826
PMCPMC11951676

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.